Info: Not Currently Available in Canada
Urolithin A is a natural postbiotic compound (produced by beneficial bacteria during the course of fermentation*) that promotes mitochondrial function (the parts of our cells which produce usable energy from food, among other things) and mitophagy (the selective recycling of those mitochondria).
Product Notes:
Sold in some markets under the trade name "Mitopure," it has been the subject of a rapidly increasing number of studies indicating it improves muscle strength and has a beneficial impact on certain biomarkers of cellular health, particularly in middle-aged and older people, and is thus heralded as an anti-aging product.
Urolithin A has yet to be issued a Natural Product Number to be licensed to sell as a natural health product in Canada. We'll be sure to provide additional information on a potential Canadian launch as soon as it's available.
* In this case, the fermentation to produce Urolithin A (UA) is achieved by using gut-derived bacteria to consume foods which contain ellagitannin, such as pomegranate, strawberry, raspberry, blackberry, muscadine grapes, or walnuts.
Related Products:
Other supplements found to influence mitophagy and mitochondrial function that are available in Canada include:
NMN+ Wheat Germ (Nicotinamide Mononucleotide & Spermidine), from AOR;
Glycine + NAC (GlyNAC), from NOW; and,
RegenerLife Mitochondrial Energy Formula, from Natural Factors.
There is also a licensed natural health product specifically designed to help reverse natural muscle loss: MuscleRescue (Reginator), from Innovite.
Mitopure™ is a trademark of Amazentis SA in the USA.
Supporting Science:
D'Amico, Davide et al. “Impact of the Natural Compound Urolithin A on Health, Disease, and Aging.” Trends in Molecular Medicine, 2021.
Kothe, Breanne et al. “Urolithin A as a Potential Agent for Prevention of Age-Related Disease: A Scoping Review.” Cureus, 2023.
Singh, Anurag et al. “Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults.” Cell Reports. Medicine, 2022.